Neutrophil-mediated tumour angiogenesis: Subversion of immune responses to promote tumour growth

Seminars in Cancer Biology

Volumn 23, Issue 3, 2013, Pages 149-158

  Tazzyman, Simon ^a   Niaz, Hanan ^a   Murdoch, Craig ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Angiogenesis; Chemokine; Neutrophil; Therapy; Tumour

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GELATINASE B; GROWTH FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 8; ONCOSTATIN M; PROTEIN BV8; PROTEINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

CANCER PROGNOSIS; CANCER SURVIVAL; CELL INTERACTION; CYTOKINE RELEASE; HUMAN; IMMUNE RESPONSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ASSOCIATED NEUTROPHIL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; CHEMOTACTIC FACTORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHIL INFILTRATION; NEUTROPHILS; TUMOR BURDEN;

EID: 84876969511     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.02.003     Document Type: Review

References (110)

1. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nature Medicine 2011, 17:1359-1370.
2. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nature Reviews Cancer 2008, 8:618-631.
3. Amulic B., Cazalet C., Hayes G.L., Metzler K.D., Zychlinsky A. Neutrophil function: from mechanisms to disease. Annual Review of Immunology 2012, 30:459-489.
4. Brandau S., Dumitru C.A., Lang S. Protumor and antitumor functions of neutrophil granulocytes. Seminars in Immunopathology 2012, 10.1007/s00281-012-0344-6.
5. Dumitru C.A., Moses K., Trellakis S., Lang S., Brandau S. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunology, Immunotherapy 2012, 61:1155-1167.
6. Nielsen B.S., Timshel S., Kjeldsen L., Sehested M., Pyke C., Borregaard N., et al. 92kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. International Journal of Cancer 1996, 65:57-62.
7. Mentzel T., Brown L.F., Dvorak H.F., Kuhnen C., Stiller K.J., Katenkamp D., et al. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virchows Archiv 2001, 438:13-22.
8. Bellocq A., Antoine M., Flahault A., Philippe C., Crestani B., Bernaudin J.F., et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. American Journal of Pathology 1998, 152:83-92.
9. Fossati G., Ricevuti G., Edwards S.W., Walker C., Dalton A., Rossi M.L. Neutrophil infiltration into human gliomas. Acta Neuropathologica 1999, 98:349-354.
10. Trellakis S., Bruderek K., Dumitru C.A., Gholaman H., Gu X., Bankfalvi A., et al. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. International Journal of Cancer 2011, 129:2183-2193.
11. Zhao J.J., Pan K., Wang W., Chen J.G., Wu Y.H., Lv L., et al. The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection. PLoS One 2012, 7:e33655.
12. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: " N1" versus " N2" TAN. Cancer Cell 2009, 16:183-194.
13. Lee J., Horuk R., Rice G.C., Bennett G.L., Camerato T., Wood W.I. Characterization of two high affinity human interleukin-8 receptors. Journal of Biological Chemistry 1992, 267:16283-16287.
14. Ahuja S.K., Murphy P.M. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. Journal of Biological Chemistry 1996, 271:20545-20550.
15. Xie K. Interleukin-8 and human cancer biology. Cytokine and Growth Factor Reviews 2001, 12:375-391.
16. Wilson J., Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Seminars in Cancer Biology 2002, 12:113-120.
17. Marjon P.L., Bobrovnikova-Marjon E.V., Abcouwer S.F. Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress. Molecular Cancer 2004, 3:4.
18. Desbaillets I., Diserens A.C., de T.N., Hamou M.F., Van Meir E.G. Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Oncogene 1999, 18:1447-1456.
19. Xu L., Fidler I.J. Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Research 2000, 60:4610-4616.
20. Tazzyman S., Lewis C.E., Murdoch C. Neutrophils: key mediators of tumour angiogenesis. International Journal of Experimental Pathology 2009, 90:222-231.
21. Lazennec G., Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends in Molecular Medicine 2010, 16:133-144.
22. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clinical Cancer Research 2008, 14:6735-6741.
23. Eck M., Schmausser B., Scheller K., Brandlein S., Muller-Hermelink H.K. Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clinical and Experimental Immunology 2003, 134:508-515.
24. Cuenca R.E., Azizkhan R.G., Haskill S. Characterization of GRO alpha, beta and gamma expression in human colonic tumours: potential significance of cytokine involvement. Surgical Oncology 1992, 1:323-329.
25. Wallace A.E., Sales K.J., Catalano R.D., Anderson R.A., Williams A.R., Wilson M.R., et al. Prostaglandin F2alpha-F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C motif) ligand 1 in endometrial adenocarcinoma. Cancer Research 2009, 69:5726-5733.
26. Schteingart D.E., Giordano T.J., Benitez R.S., Burdick M.D., Starkman M.N., Arenberg D.A., et al. Overexpression of CXC chemokines by an adrenocortical carcinoma: a novel clinical syndrome. Journal of Clinical Endocrinology and Metabolism 2001, 86:3968-3974.
27. Frick V.O., Rubie C., Wagner M., Graeber S., Grimm H., Kopp B., et al. Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases. Pancreatology 2008, 8:488-497.
28. Li A., King J., Moro A., Sugi M.D., Dawson D.W., Kaplan J., et al. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. American Journal of Pathology 2011, 178:1340-1349.
29. Begley L.A., Kasina S., Mehra R., Adsule S., Admon A.J., Lonigro R.J., et al. CXCL5 promotes prostate cancer progression. Neoplasia 2008, 10:244-254.
30. Okabe H., Beppu T., Ueda M., Hayashi H., Ishiko T., Masuda T., et al. Identification of CXCL5/ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts. International Journal of Cancer 2012, 131:2234-2241.
31. Zhou S.L., Dai Z., Zhou Z.J., Wang X.Y., Yang G.H., Wang Z., et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology 2012, 56:22242-22254.
32. Dimberg J., Dienus O., Lofgren S., Hugander A., Wagsater D. Expression and gene polymorphisms of the chemokine CXCL5 in colorectal cancer patients. International Journal of Oncology 2007, 31:97-102.
33. Gijsbers K., Gouwy M., Struyf S., Wuyts A., Proost P., Opdenakker G., et al. GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. Experimental Cell Research 2005, 303:331-342.
34. Matsui A., Yokoo H., Negishi Y., Endo-Takahashi Y., Chun N.A., Kadouchi I., et al. CXCL17 expression by tumor cells recruits CD11b(+)Gr1(high)F4/80(-) cells and promotes tumor progression. PLoS One 2012, 7:e44080.
35. Tazzyman S., Barry S.T., Ashton S., Wood P., Blakey D., Lewis C.E., et al. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. International Journal of Cancer 2011, 129:847-858.
36. Bru A., Souto J.C., Alcolea S., Anton R., Remacha A., Camacho M., et al. Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatment. Mediators of Inflammation 2009, 2009:817498.
37. Dumitru C.A., Gholaman H., Trellakis S., Bruderek K., Dominas N., Gu X., et al. Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. International Journal of Cancer 2011, 129:859-869.
38. Conroy H., Mawhinney L., Donnelly S.C. Inflammation and cancer: macrophage migration inhibitory factor (MIF)-the potential missing link. QJM 2010, 103:831-836.
39. Larsen M., Tazzyman S., Lund E.L., Junker N., Lewis C.E., Kristjansen P.E., et al. Hypoxia-induced secretion of macrophage migration-inhibitory factor from MCF-7 breast cancer cells is regulated in a hypoxia-inducible factor-independent manner. Cancer Letters 2008, 265:239-249.
40. Winner M., Koong A.C., Rendon B.E., Zundel W., Mitchell R.A. Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Research 2007, 67:186-193.
41. Bernhagen J., Krohn R., Lue H., Gregory J.L., Zernecke A., Koenen R.R., et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nature Medicine 2007, 13:587-596.
42. Chuntharapai A., Lee J., Hebert C.A., Kim K.J. Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. Journal of Immunology 1994, 153:5682-5688.
43. Loetscher M., Geiser T., O'Reilly T., Zwahlen R., Baggiolini M., Moser B. Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. Journal of Biological Chemistry 1994, 269:232-237.
44. Martin J., Duncan F.J., Keiser T., Shin S., Kusewitt D.F., Oberyszyn T., et al. Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB) -induced nonmelanoma skin cancer (NMSC). FASEB Journal 2009, 23:720-730.
45. Ni C., Zhao X., Sun T., Liu Y., Gu Q., Sun B. Role of gastrin-releasing peptides in breast cancer metastasis. Human Pathology 2012, 43:2342-2347.
46. Czepielewski R.S., Porto B.N., Rizzo L.B., Roesler R., Abujamra A.L., Pinto L.G., et al. Gastrin-releasing peptide receptor (GRPR) mediates chemotaxis in neutrophils. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:547-552.
47. Gebhardt C., Nemeth J., Angel P., Hess J. S100A8 and S100A9 in inflammation and cancer. Biochemical Pharmacology 2006, 72:1622-1631.
48. Ryckman C., Vandal K., Rouleau P., Talbot M., Tessier P.A. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. Journal of Immunology 2003, 170:3233-3242.
49. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
50. Orlova V.V., Choi E.Y., Xie C., Chavakis E., Bierhaus A., Ihanus E., et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO Journal 2007, 26:1129-1139.
51. Van Coillie E., Van Aelst I., Wuyts A., Vercauteren R., Devos R., De Wolf-Peeters C., et al. Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle. American Journal of Pathology 2001, 159:1405-1414.
52. Nozawa H., Chiu C., Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:12493-12498.
53. Amini A., Moghaddam S.M., Morris D.L., Pourgholami M.H. The critical role of vascular endothelial growth factor in tumor angiogenesis. Current Cancer Drug Targets 2012, 12:23-43.
54. Kusumanto Y.H., Dam W.A., Hospers G.A., Meijer C., Mulder N.H. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003, 6:283-287.
55. Gaudry M., Bregerie O., Andrieu V., El B.J., Pocidalo M.A., Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997, 90:4153-4161.
56. McCourt M., Wang J.H., Sookhai S., Redmond H.P. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Archives of Surgery 1999, 134:1325-1331.
57. Jablonska E., Puzewska W., Grabowska Z., Jablonski J., Talarek L. VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine 2005, 30:93-99.
58. Jablonska J., Leschner S., Westphal K., Lienenklaus S., Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. Journal of Clinical Investigation 2010, 120:1151-1164.
59. Schonbeck U., Brandt E., Petersen F., Flad H.D., Loppnow H. IL-8 specifically binds to endothelial but not to smooth muscle cells. Journal of Immunology 1995, 154:2375-2383.
60. Koch A.E., Polverini P.J., Kunkel S.L., Harlow L.A., DiPietro L.A., Elner V.M., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258:1798-1801.
61. Murdoch C., Monk P.N., Finn A. Cxc chemokine receptor expression on human endothelial cells. Cytokine 1999, 11:704-712.
62. Yoo J.Y., Kim J.H., Kim J., Huang J.H., Zhang S.N., Kang Y.A., et al. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Therapy 2008, 15:635-651.
63. Arenberg D.A., Kunkel S.L., Polverini P.J., Glass M., Burdick M.D., Strieter R.M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. Journal of Clinical Investigation 1996, 97:2792-2802.
64. Bendrik C., Dabrosin C. Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. Journal of Immunology 2009, 182:371-378.
65. Yeudall W.A., Vaughan C.A., Miyazaki H., Ramamoorthy M., Choi M.Y., Chapman C.G., et al. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 2012, 33:442-451.
66. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
67. Strieter R.M., Polverini P.J., Kunkel S.L., Arenberg D.A., Burdick M.D., Kasper J., et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. Journal of Biological Chemistry 1995, 270:27348-27357.
68. Scapini P., Lapinet-Vera J.A., Gasperini S., Calzetti F., Bazzoni F., Cassatella M.A. The neutrophil as a cellular source of chemokines. Immunological Reviews 2000, 177:195-203.
69. LeCouter J., Lin R., Tejada M., Frantz G., Peale F., Hillan K.J., et al. The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: localization of Bv8 receptors to endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:2685-2690.
70. Shojaei F., Singh M., Thompson J.D., Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:2640-2645.
71. Zhong C., Qu X., Tan M., Meng Y.G., Ferrara N. Characterization and regulation of bv8 in human blood cells. Clinical Cancer Research 2009, 15:2675-2684.
72. Qu X., Zhuang G., Yu L., Meng G., Ferrara N. Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. Journal of Biological Chemistry 2012, 287:19574-19584.
73. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:6742-6747.
74. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
75. Lorenzon P., Vecile E., Nardon E., Ferrero E., Harlan J.M., Tedesco F., et al. Endothelial cell E- and P-selectin and vascular cell adhesion molecule-1 function as signaling receptors. Journal of Cell Biology 1998, 142:1381-1391.
76. Durieu-Trautmann O., Chaverot N., Cazaubon S., Strosberg A.D., Couraud P.O. Intercellular adhesion molecule 1 activation induces tyrosine phosphorylation of the cytoskeleton-associated protein cortactin in brain microvessel endothelial cells. Journal of Biological Chemistry 1994, 269:12536-12540.
77. Yasuda M., Shimizu S., Ohhinata K., Naito S., Tokuyama S., Mori Y., et al. Differential roles of ICAM-1 and E-selectin in polymorphonuclear leukocyte-induced angiogenesis. American Journal of Physiology: Cell Physiology 2002, 282:C917-C925.
78. Iwasaka C., Tanaka K., Abe M., Sato Y. Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. Journal of Cellular Physiology 1996, 169:522-531.
79. Oda N., Abe M., Sato Y. ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. Journal of Cellular Physiology 1999, 178:121-132.
80. Yasuda M., Shimizu S., Tokuyama S., Watanabe T., Kiuchi Y., Yamamoto T. A novel effect of polymorphonuclear leukocytes in the facilitation of angiogenesis. Life Sciences 2000, 66:2113-2121.
81. Mott J.D., Werb Z. Regulation of matrix biology by matrix metalloproteinases. Current Opinion in Cell Biology 2004, 16:558-564.
82. Deryugina E.I., Quigley J.P. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochimica et Biophysica Acta 2010, 1803:103-120.
83. Kuang D.M., Zhao Q., Wu Y., Peng C., Wang J., Xu Z., et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. Journal of Hepatology 2011, 54:948-955.
84. Bausch D., Pausch T., Krauss T., Hopt U.T., Fernandez-del-Castillo C., Warshaw A.L., et al. Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. Angiogenesis 2011, 14:235-243.
85. Murphy G. Tissue inhibitors of metalloproteinases. Genome Biology 2011, 12:233.
86. Ardi V.C., Van den Steen P.E., Opdenakker G., Schweighofer B., Deryugina E.I., Quigley J.P. Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. Journal of Biological Chemistry 2009, 284:25854-25866.
87. Ardi V.C., Kupriyanova T.A., Deryugina E.I., Quigley J.P. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:20262-20267.
88. Bekes E.M., Schweighofer B., Kupriyanova T.A., Zajac E., Ardi V.C., Quigley J.P., et al. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. American Journal of Pathology 2011, 179:1455-1470.
89. Shamamian P., Schwartz J.D., Pocock B.J., Monea S., Whiting D., Marcus S.G., et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. Journal of Cellular Physiology 2001, 189:197-206.
90. Grenier A., Dehoux M., Boutten A., rce-Vicioso M., Durand G., Gougerot-Pocidalo M.A., et al. Oncostatin M production and regulation by human polymorphonuclear neutrophils. Blood 1999, 93:1413-1421.
91. Queen M.M., Ryan R.E., Holzer R.G., Keller-Peck C.R., Jorcyk C.L. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Research 2005, 65:8896-8904.
92. Modur V., Feldhaus M.J., Weyrich A.S., Jicha D.L., Prescott S.M., Zimmerman G.A., et al. Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. Journal of Clinical Investigation 1997, 100:158-168.
93. Elbjeirami W.M., Donnachie E.M., Burns A.R., Smith C.W. Endothelium-derived GM-CSF influences expression of oncostatin M. American Journal of Physiology: Cell Physiology 2011, 301:C947-C953.
94. Patterson B.C., Sang Q.A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). Journal of Biological Chemistry 1997, 272:28823-28825.
95. Scapini P., Nesi L., Morini M., Tanghetti E., Belleri M., Noonan D., et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. Journal of Immunology 2002, 168:5798-5804.
96. Kurtagic E., Jedrychowski M.P., Nugent M.A. Neutrophil elastase cleaves VEGF to generate a VEGF fragment with altered activity. American Journal of Physiology: Lung Cellular and Molecular Physiology 2009, 296:L534-L546.
97. Ai S., Cheng X.W., Inoue A., Nakamura K., Okumura K., Iguchi A., et al. Angiogenic activity of bFGF and VEGF suppressed by proteolytic cleavage by neutrophil elastase. Biochemical and Biophysical Research Communications 2007, 364:395-401.
98. Benelli R., Morini M., Carrozzino F., Ferrari N., Minghelli S., Santi L., et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB Journal 2002, 16:267-269.
99. Conti I., Rollins B.J. CCL2 (monocyte chemoattractant protein-1) and cancer. Seminars in Cancer Biology 2004, 14:149-154.
100. Tsuda Y., Takahashi H., Kobayashi M., Hanafusa T., Herndon D.N., Suzuki F. Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity 2004, 21:215-226.
101. Lin E.Y., Li J.F., Gnatovskiy L., Deng Y., Zhu L., Grzesik D.A., et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Research 2006, 66:11238-11246.
102. Pahler J.C., Tazzyman S., Erez N., Chen Y.Y., Murdoch C., Nozawa H., et al. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 2008, 10:329-340.
103. Gregory A.D., Houghton A.M. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Research 2011, 71:2411-2416.
104. Kazemfar K., Chen R., Nicholson K., Coppola D., Zhou J.M., Chen X., et al. Combined IL-8 and TGF-beta blockade efficiently prevents neutrophil infiltrates into an A549-cell tumor. Immunology Letters 2009, 122:26-29.
105. Rao H.L., Chen J.W., Li M., Xiao Y.B., Fu J., Zeng Y.X., et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis. PLoS One 2012, 7:e30806.
106. Li Y.W., Qiu S.J., Fan J., Zhou J., Gao Q., Xiao Y.S., et al. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. Journal of Hepatology 2011, 54:497-505.
107. Jensen T.O., Schmidt H., Moller H.J., Donskov F., Hoyer M., Sjoegren P., et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2012, 118:2476-2485.
108. Ilie M., Hofman V., Ortholan C., Bonnetaud C., Coelle C., Mouroux J., et al. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer 2012, 118:1726-1737.
109. Jensen H.K., Donskov F., Marcussen N., Nordsmark M., Lundbeck F., von der M.H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. Journal of Clinical Oncology 2009, 27:4709-4717.
110. Schwaller J., Schneider P., Mhawech-Fauceglia P., McKee T., Myit S., Matthes T., et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 2007, 109:331-338.